Go Back This article was viewed 103 times

Editorial


Nanobyte

Radhika A. Vaishnav
Department of Clinical Research, Vadodara Stroke Center, Director, Natureka Life Sciences, Vadodara, Gujarat, India
Corresponding Author:

Radhika A. Vaishnav

Department of Clinical Research, Vadodara Stroke Center, Director, Natureka Life Sciences, Vadodara, Gujarat, India
E-mail: radhikavaishnav@gmail.com

Corresponding Author:

Radhika A. Vaishnav

Department of Clinical Research, Vadodara Stroke Center, Director, Natureka Life Sciences, Vadodara, Gujarat, India
E-mail: radhikavaishnav@gmail.com

DOI:10.18203/issn.2456-3994.IntJMolImmunoOncol20183224

ABSTRACT


An unintended effect of CRISPR-Cas-9 gene therapy may be the natural selection of p53-deficient cells. While this was unexpected, it highlights the need for continued basic research and carefully designed clinical trials to evaluate the mechanism and safety of this outcome.
Keywords: Gene editing, p53, Tumor suppressor, Side effects, CRISPR-Cas9

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.